Want to see HROW full AI Analyst Report?
HROW Stock Chart & Stats
$41.33
-$0.70(-1.82%)
At close: 4:00 PM EDT
$41.33
-$0.70(-1.82%)
Day’s Range― - ―
52-Week Range$26.96 - $54.85
Previous CloseN/A
Volume279.61K
Average Volume (3M)632.41K
Market Cap
$1.09B
Enterprise Value$1.80B
Total Cash (Recent Filing)$83.89M
Total Debt (Recent Filing)$300.74M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Nov 09, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding37,487,850
10 Day Avg. Volume610,430
30 Day Avg. Volume632,406
Financial Highlights & Ratios
PEG Ratio4.90
Price to Book (P/B)34.35
Price to Sales (P/S)6.61
P/FCF Ratio42.12
Enterprise Value/Market Cap1.66
Enterprise Value/Revenue6.54
Enterprise Value/Gross Profit8.93
Enterprise Value/Ebitda161.15
Forecast
1Y Price Target
$64.33Price Target Upside55.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$350.28M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginStrong sales growth combined with high gross margins indicates attractive product economics and increasing commercial traction. If sustained, this mix can provide the contribution needed to absorb operating investments, support cash generation, and improve earnings potential over the next several quarters.
Multi-Product Demand MomentumVEVYE is demonstrating durable adoption through rising prescriptions, a broader prescriber base, and expanding branded share. Growth across this franchise, alongside demand for IHEEZO and TRIESENCE, gives Harrow multiple commercial drivers rather than reliance on a single product.
TYRVAYA Portfolio ExpansionThe completed TYRVAYA acquisition broadens Harrow’s dry-eye offering and adds an established commercial asset to its existing infrastructure. The added product and personnel could deepen physician coverage, improve portfolio breadth, and create a meaningful revenue contributor beyond the current product base.
Bears Say
Higher Leverage And Thin EquityA more debt-funded balance sheet reduces financial flexibility if operating performance weakens and increases the importance of sustained cash generation. Higher leverage can also constrain capital allocation, raise refinancing exposure, and make future growth investments more dependent on execution.
Widening Net LossesWidening losses show that strong product-level economics have not yet translated into consistent company-wide profitability. Elevated operating or non-operating costs may continue to absorb gross profit, limiting retained cash, reducing resilience, and making the path to durable earnings more execution-sensitive.
Second-Half Execution RiskMeeting the reiterated annual outlook requires a substantial acceleration in the second half, placing significant dependence on channel normalization, VEVYE growth, salesforce productivity, and TYRVAYA integration. Any delay across these initiatives could weaken revenue delivery and postpone operating leverage.
Harrow Health News
HROW FAQ
What was Harrow Health Inc’s price range in the past 12 months?
Harrow Health Inc lowest stock price was $26.96 and its highest was $54.85 in the past 12 months.
What is Harrow Health Inc’s market cap?
Harrow Health Inc’s market cap is $1.09B.
When is Harrow Health Inc’s upcoming earnings report date?
Harrow Health Inc’s upcoming earnings report date is Nov 09, 2026 which is in 13 days.
How were Harrow Health Inc’s earnings last quarter?
Harrow Health Inc released its earnings results on Aug 10, 2026. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.179 by -$0.281.
Is Harrow Health Inc overvalued?
According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued.
Does Harrow Health Inc pay dividends?
Harrow Health Inc does not currently pay dividends.
What is Harrow Health Inc’s EPS estimate?
Harrow Health Inc’s EPS estimate is 0.19.
How many shares outstanding does Harrow Health Inc have?
Harrow Health Inc has 37,487,850 shares outstanding.
What happened to Harrow Health Inc’s price movement after its last earnings report?
Harrow Health Inc reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.179. Following the earnings report the stock price went down -3.145%.
Which hedge fund is a major shareholder of Harrow Health Inc?
Currently, no hedge funds are holding shares in HROW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harrow Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.33 (55.66% Upside)
$64.33 (55.66% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 83%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 89.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $450.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.84%
12-Months-Change
Fundamentals
Return on Equity
-103.86%
Trailing 12-Months
Asset Growth
20.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Harrow Health Inc
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
HROW Company Deck
HROW Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum across multiple franchises (VEVYE, IHEEZO, TRIESENCE), record unit demand, successful market-access wins, pipeline progress (pre-NDA for MELT-300), and reiterated full-year guidance—supporting an optimistic outlook. Offsetting risks include a weaker-than-expected first half, negative adjusted EBITDA in the quarter, channel inventory/revenue timing effects, the need for a sizable second-half revenue ramp to meet guidance, and near-term SG&A and acquisition-related cash outflows. On balance, management presented credible operational and commercial drivers to achieve the required second-half acceleration, but execution and integration risks remain material.View all HROW earnings summariesHROW Stock 12 Month Forecast
Average Price Target
$64.33
▲(55.66% Upside)
Technical Analysis
Perrigo Company
―
ANI Pharmaceuticals
―
Cumberland Pharmaceuticals
―
Amneal Pharmaceuticals
―
Eton Pharmaceuticals
―
Ownership Overview
19.99% Insiders
9.67% Mutual Funds
0.48% Other Institutional Investors
57.04% Public Companies and
Individual Investors